Consensus
The community sees this as unlikely for Novartis at 33%, based on 7 forecasts. Forecasters are in moderate agreement.
Resolves YES if Novartis is up more than 18% 180 days out versus its baseline price.
Share your read on this question — the best forecasters show their work.
See the whole nvs discussion →